After thinking he just had a stubborn sinus infection that wouldn't go away, Brian McNamara was told he had an ultra-rare ...

Chinese and international oncologists witness the release of a breakthrough finding by a Chinese pharma company during the ...

Researchers conducted a prospective, longitudinal cohort study involving individuals with current or former habit, who had ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

Due to the destructive nature of COPD on patients’ lungs and well-being, timely diagnosis is key, and integrating spirometry ...

In the growing field of personalized medicine, scientists at Yale University have found promising evidence that a simple ...

Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

After breaking his hand and injuring his shoulder last year, Brian sought out much-needed medical attention, which led to him learning that he had cancer.

Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor ...

Biliary Tract Cancer (BTC): KEYTRUDA may be combined with chemotherapy medicines to treat BTC, a cancer that affects the bile ducts or gallbladder. This treatment is for adults when the cancer has ...